AC Immune SA (ACIU)
2.935
+0.08
(+2.62%)
USD |
NASDAQ |
Aug 25, 16:00
2.935
0.00 (0.00%)
After-Hours: 19:35
AC Immune Shareholders Equity (Quarterly) : 43.60M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 43.60M |
| March 31, 2026 | 39.24M |
| December 31, 2025 | 56.65M |
| September 30, 2025 | 78.48M |
| June 30, 2025 | 93.90M |
| March 31, 2025 | 107.15M |
| December 31, 2024 | 123.88M |
| September 30, 2024 | 154.31M |
| June 30, 2024 | 137.35M |
| March 31, 2024 | 160.63M |
| December 31, 2023 | 190.87M |
| September 30, 2023 | 137.37M |
| June 30, 2023 | 155.73M |
| March 31, 2023 | 167.41M |
| December 31, 2022 | 182.65M |
| September 30, 2022 | 193.10M |
| June 30, 2022 | 211.85M |
| March 31, 2022 | 232.69M |
| December 31, 2021 | 254.60M |
| September 30, 2021 | 192.12M |
| June 30, 2021 | 204.77M |
| March 31, 2021 | 220.39M |
| December 31, 2020 | 243.77M |
| Date | Value |
|---|---|
| September 30, 2020 | 253.87M |
| June 30, 2020 | 264.75M |
| March 31, 2020 | 274.51M |
| December 31, 2019 | 281.35M |
| September 30, 2019 | 293.22M |
| June 30, 2019 | 280.30M |
| March 31, 2019 | 242.85M |
| December 31, 2018 | 180.18M |
| September 30, 2018 | 196.54M |
| June 30, 2018 | 96.07M |
| March 31, 2018 | 110.51M |
| December 31, 2017 | 119.90M |
| September 30, 2017 | 116.44M |
| June 30, 2017 | 126.24M |
| March 31, 2017 | 132.93M |
| December 31, 2016 | 140.09M |
| September 30, 2016 | 150.82M |
| June 30, 2016 | 92.94M |
| March 31, 2016 | 67.54M |
| December 31, 2015 | 70.97M |
| September 30, 2015 | 49.28M |
| June 30, 2015 | 31.04M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 5.174B |
| CRISPR Therapeutics AG | 1.747B |
| Idorsia Ltd. | -1.480B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 186.45M |
| Total Liabilities (Quarterly) | 142.85M |
| Debt to Equity Ratio | 0.1166 |
| Current Ratio | 0.9318 |
| Net Debt Paydown Yield | 0.07% |